PFAS in Breast Milk: A Global Monitoring Picture
Human breast milk—the optimal nutrition for infants and a cornerstone of maternal-infant bonding and immune development—contains per- and polyfluoroalkyl substances in populations worldwide. PFAS transfer from maternal blood to breast milk at concentrations representing approximately 1–5% of maternal serum levels for most PFAS compounds. While this fraction is small, the combination of maternal body burdens accumulated over a lifetime of PFAS exposure and infants’ much higher daily fluid intake relative to body weight means that breastfed infants receive meaningful PFAS doses through breast milk—a finding documented across North America, Europe, Asia, and increasingly in developing world contexts.
Global Breast Milk PFAS Monitoring Data
Systematic breast milk PFAS monitoring has been conducted in: United States: CDC NHANES supplemental breast milk study found PFOS in 100% and PFOA in 95% of samples, with median PFOS of 0.098 ng/mL. Norway: Norwegian Institute of Public Health monitoring shows declining trends (PFOS median: 0.12 ng/mL, 2018) following global production phase-outs. China: PFAS in breast milk from industrial cities (Guangzhou, Hangzhou) show significantly higher concentrations than rural areas—PFOS median 0.45 ng/mL in industrial regions. Sweden: Long-running monitoring shows 70% decline in PFOS from 1996 to 2020, from 0.8 ng/mL to 0.08 ng/mL—demonstrating the effectiveness of PFAS source reduction. Japan: PFAS in breast milk from Tokyo and Osaka show PFOS median of 0.18 ng/mL in 2018 surveys. Senegal/Tanzania: Breast milk PFAS in West and East African cities comparable to European urban populations—reflecting global consumer product contamination.
Health Agency Guidance: The Continuing Recommendation
Despite the presence of PFAS in breast milk, every major health organization globally—WHO, American Academy of Pediatrics, EFSA, CDC, and national health ministries—continues to recommend breastfeeding as the optimal infant nutrition strategy. The evidence base supporting this guidance: breastfeeding provides substantial protection against infant respiratory infections, gastroenteritis, necrotizing enterocolitis, and sudden infant death syndrome; immune benefits from breast milk (antibodies, prebiotics, immune cells) are not replicable in formula; early-life microbiome development is significantly influenced by breast milk composition; and the neurological and cognitive benefits of breastfeeding are well-documented. Health authorities judge that these established benefits outweigh the modeled PFAS risk from breast milk exposure—particularly given that formula-fed infants may also have PFAS exposure from formula preparation with contaminated water.
The Case for Maternal PFAS Reduction
While breastfeeding recommendations remain unchanged, health researchers emphasize that the appropriate response to PFAS in breast milk is reducing maternal exposure before and during pregnancy—not discouraging breastfeeding. Key maternal PFAS reduction strategies: eliminating PFAS from drinking water through certified filtration (the largest controllable exposure source); avoiding PFAS-treated food packaging, nonstick cookware, and stain-resistant textiles; choosing PFAS-free personal care products. A 2022 study found that women who implemented comprehensive PFAS-reduction strategies during pregnancy showed breast milk PFAS concentrations approximately 30% lower than matched controls—demonstrating that individual exposure reduction is achievable. For water filter manufacturers, the breast milk PFAS pathway provides a compelling health communication message for promoting certified point-of-use filtration to women of reproductive age.
The presence of PFAS in breast milk is not a reason to discourage breastfeeding—it is a reason to eliminate PFAS from sources that create maternal body burden, with drinking water filtration as the most effective controllable intervention.